Hepatitis C treatment in combination with amiodarone: risk of severe bradycardia

24 August 2015

Patients receiving combination therapy with simeprevir (Olysio) and sofosbuvir (Sovaldi) should avoid concomitant use of amiodarone, unless other antiarrhythmics cannot be given.

Following the May issue of Drug Safety Update, the MHRA has extended its advice regarding the use of sofosbuvir combination therapy with amiodarone, to now include simeprevir.

Advice for monitoring patients receiving concomitant amiodarone and with cardiac rhythm disorders and hepatitis C can be found here.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

The most up-to-date drug information at your fingertips.

  • Get the prescribing support you need.
  • Register today for full access to the MIMS database, plus tables and guideline summaries, new and deleted products and consultation tools.
Register Now
Already Registered?

Forgotten password?

More from MIMS

Male clinician in white coat showing female patient how to use IQoro device.

Training device for reflux and dysphagia available on NHS

A neuromuscular training device for patients with reflux-based...

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...